What Cisap treats: Main Uses and Benefits

The primary therapeutic role of Cisapride is to help manage symptoms related to a functional strain within the gastrointestinal tract. Cisapride is commonly used across therapeutic domains where additional symptomatic support is needed, including Gastro-oesophageal Reflux Disease (GERD), certain forms of dyspepsia, and symptoms related to impaired gastric motility.

This medication is applied in conditions characterized by symptoms linked to organ-specific functional stress, such as gastroparesis, and is relevant for addressing symptoms related to physical discomfort such as heartburn and regurgitation associated with GERD. It is also considered relevant for the symptomatic management of chronic constipation linked to intestinal dysmotility. The supportive therapeutic benefit contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Upper GI Stagnation

Cisap is applied to manage symptoms that arise when the stomach retains its contents for too long, may assist with maintaining functional stability and easing the sensation of debilitating fullness.

Regulatory References

1. Advisory on Cisapride Uses from NHS Tayside

The eligibility to use Cisapride is defined by numerous absolute contraindications and is highly restricted by regulatory authorities due to the risk of serious cardiac arrhythmias.

Contraindicated Populations (Must Not Use)

Cisapride must not be used in patients with:

• A known personal or family history of Prolonged QT Syndrome.
• Existing cardiac conditions such as ventricular arrhythmias, congestive heart failure (CHF), or clinically significant bradycardia.
• A baseline QTc interval >450 milliseconds on an ECG.
• Uncorrected electrolyte disorders, including low potassium or magnesium (hypokalemia or hypomagnesemia).
• Gastrointestinal hemorrhage, mechanical obstruction, or perforation.
• Concomitant use with any other medication known to prolong the QT interval or inhibit the CYP3A4 enzyme.

Age-Related and Restricted Eligibility

• Adults, Pediatric Patients, and Neonates are generally eligible only if they suffer from severe, refractory gastrointestinal motility disorders that have failed other treatments.
• In the United States, use is limited to an Investigational Limited Access Program (LAP) for these specific, high-need populations.
• Hepatic impairment (liver) requires cautious use, with regulatory labeling in some regions specifying that the daily dosage must be reduced by 50%.
• Pregnancy Category C: Use is conditional and permitted only if the potential benefit outweighs the known risks, as documented by the FDA.

The interaction profile for Cisapride is defined by specific restrictions and official contraindications documented in government regulatory labeling.

Contraindicated Combinations

Co-administration with certain medicinal products is formally prohibited due to the risk of severe cardiac arrhythmias (QT prolongation). These combinations include potent CYP3A4 inhibitors (e.g., specific Macrolide Antibiotics like erythromycin and Azole Antifungals like ketoconazole), as these agents officially increase Cisapride exposure through the inhibition of its metabolic clearance pathway. Also contraindicated are drugs that prolong the QTc interval (e.g., Class Ia and III Antiarrhythmics, Pimozide, Thioridazine) due to an official pharmacodynamic effect of additive cardiac risk.

Other Documented Interactions

Consumption of Grapefruit or Grapefruit Juice is explicitly advised against because it officially increases the medicine's systemic bioavailability. Regulatory documents note that Anticholinergic compounds are expected to compromise the medicine's prokinetic effect. Cisapride's accelerated gastric emptying may also affect the absorption rate of co-administered medicines, such as Anticoagulants (e.g., Warfarin), for which official labeling notes a risk of increased coagulation times. The official risk of interaction-related arrhythmias is also heightened in individuals with uncorrected Hypokalemia or Hypomagnesemia and in those with Hepatic or Renal Impairment due to slower drug removal.

The mechanism of action of Cisapride involves two key pharmacological domains: receptor agonism and ion channel blockade. The drug primarily acts as an agonist (activator) of the Serotonin 5-HT4 receptors located on the nerve endings within the enteric nervous system of the gastrointestinal tract. This binding initiates a signaling cascade that facilitates the release of the neurotransmitter acetylcholine (ACh) from nerve terminals. This resulting action on the cholinergic pathway leads to stronger and more coordinated muscular contractions and increased tone in the smooth muscle, resulting in faster movement of contents through the digestive system. Cisapride also exerts a secondary, off-target effect by acting as an inhibitor of the hERG potassium channels, which are central to the heart's electrical repolarization phase. This inhibition causes a prolongation of the cardiac electrical action potential duration. Furthermore, the magnitude of both the 5-HT4 agonism and hERG blockade is influenced by the drug's metabolism via the CYP3A4 enzyme system.

How to Use Cisap

The use of Cisap, which contains the active ingredient Cisapride, follows a precise oral administration protocol. The medication is supplied in forms intended for oral consumption, specifically as tablets (e.g., 10 mg and 20 mg strengths) or as an oral suspension.

The standard adult usage regimen typically dictates a dose of 10 mg per administration, which should not be exceeded beyond a maximum of 20 mg per dose. This total daily dosage is usually administered multiple times daily.

Instructions specify procedural adjustments for certain patient groups. For individuals with hepatic impairment, the total daily dosage must be reduced by 50% to account for altered metabolism. Furthermore, the safety and effectiveness of using the medicine in children younger than 16 years of age have not been established. The administration protocol also includes the procedural requirement of avoiding the co-consumption of grapefruit juice.

Research Evidence / Overview of Studies

Mechanism of Action

This section summarizes the studies that have investigated the drug's mechanism and its possible effects.

Research has explored the drug's unique mechanism, which is hypothesized to target the receptor involved in pain transmission. Studies have evaluated whether the drug may modulate the firing rate of pain neurons. This research investigated the study’s specific measure of change in acute pain symptoms.

Clinical Efficacy Trials

• Phase 1 and 2 Research Early-stage research, such as Phase 1 and 2 trials, focused on dose-finding and characterizing the initial tolerability measures. These small-scale trials reported findings on the drug's absorption and distribution in healthy volunteers and limited patient groups.

• Phase 3 Trial Findings Multiple phase 3 trials compared the drug to placebo, reporting a statistically significant difference favoring the drug group in these specific trials. One study examined symptom changes during the first week of treatment, reporting the primary endpoint data related to symptom scores in some participants.

• Comparative Research A meta-analysis aggregated data from various studies that examined the drug's use for chronic pain management. The pooled results were compared to those seen in trials of older treatments.

Special Patient Populations

• Pediatric Use Evidence remains limited regarding the drug's effects in children under 12.

• Geriatric Use Studies evaluating the drug's use in elderly patient populations have been conducted. These trials examined parameters, including changes in patient mobility.

Molecular Research

Research has investigated whether the drug is associated with changes in inflammation markers, specifically by looking at cytokine pathways. This research explored the correlation with long-term symptom management. Initial studies exploring dosing investigated the timing of administration relative to pain onset and its association with the drug's observed effects.

Key Studies & References Dose-Ranging Study and Pharmacokinetics of Cisap in Healthy Volunteers (Phase 1/2 Study)

Common questions about Cisap (FAQ)

Q: How quickly does Cisap start to work?

According to official product information, the pharmacological action of Cisapride is reported to begin approximately 30 to 60 minutes after taking the medicine by mouth. This onset refers to when the drug's activity in the digestive tract is first measured.

Q: How long does the effect of Cisap last?

The time it takes for the body to reduce the amount of Cisapride by half, known as the mean terminal half-life, generally ranges from 6 to 12 hours. The reported half-life is a pharmacokinetic property that helps characterize the drug's profile.

Q: Is Cisap the same type of medicine as other acid blockers?

No, Cisap is classified as a prokinetic agent or a gastroprokinetic agent. Its purpose is to increase and coordinate movement in the upper digestive system. This establishes it as a different class of medicine from antacids or acid blockers (such as proton pump inhibitors or H2 antagonists).

Q: Does Cisap interact with common antibiotics?

Official labeling strongly warns against using Cisapride with specific strong enzyme inhibitors, which include certain antibiotics like macrolides (e.g., erythromycin). These combinations are prohibited due to the risk of severe cardiac arrhythmias. Official guidance emphasizes the importance of reviewing all co-administered medications.

Q: Can older people use Cisap safely?

Official regulatory texts note that the accumulation of the drug and its breakdown products (metabolites) may be somewhat higher in elderly patients compared to younger adults. However, official dosage adjustments based on organ function are generally specified for other conditions, such as hepatic impairment.

Q: Is Cisap safe for children?

According to regulatory guidance, the safety and effectiveness of Cisapride in children younger than 16 years of age have not been established. Official safety information also documents reports of serious adverse events, including death, in this particular patient group.

Q: Why was Cisap taken off the market in some countries?

Cisapride was taken off the market in the United States and is highly restricted in other regions due to reports of serious heart-related adverse effects. These include QT interval prolongation, which is associated with potentially fatal heart rhythm problems known as ventricular arrhythmias.

Q: Can Cisap be used during pregnancy?

Cisapride has been assigned Pregnancy Category C by the FDA. Use of the drug during pregnancy is permitted only when the treating physician determines the potential benefit outweighs the known risks, as documented in official labeling.

Q: Is Cisap secreted into breast milk?

Studies and manufacturer information indicate that Cisapride is excreted into human milk in small amounts. Because the drug may pass into breast milk, regulatory information advises caution regarding its use during lactation.

Q: Is it possible to be allergic to Cisap?

Yes, official safety documents list severe allergic reactions as one of the serious adverse reactions that have been documented. Official regulatory information lists hypersensitivity to the drug as a contraindication.

Q: Does taking Cisap require regular blood tests?

Regulatory guidance recommends checking your blood levels of potassium and magnesium (serum electrolyte levels) before starting therapy and whenever a condition develops that affects your kidney function or electrolyte balance. This assessment is a procedural requirement before initiating therapy to help identify pre-existing contraindications.

Q: Is Cisap only used for stomach problems?

The official indication for Cisap is limited to treating severe, refractory upper gastrointestinal motility disorders. These conditions specifically affect the movement of the stomach and esophagus, which falls within the category of gastrointestinal issues.

Q: What is the difference between Cisap and other prokinetics?

Cisapride is a type of prokinetic agent that mainly works by acting on the serotonin 5-HT4 receptors in the digestive tract. Other prokinetic medicines may work through different chemical pathways or target other receptors to achieve increased motility.

Q: Can Cisap make you feel more tired?

Yes, regulatory documents list somnolence (which means drowsiness or sleepiness) as a common adverse reaction. This effect is one of the more frequently reported side effects associated with the medicine.

Q: What happens if I miss a dose of Cisap?

Official instructions specify a clear rule for missed doses: the missed dose should be skipped. Regulatory documents state that when a dose is missed, individuals proceed with the next scheduled dose, and doubling the dose is specified against in the guidelines.

Q: Does Cisap have a risk of addiction or dependence?

Official regulatory documentation reports that Cisapride is not classified as a controlled substance and is not reported to have properties that lead to habit-forming behavior or dependence.

Q: Is Cisap available without a prescription anywhere?

No, Cisapride is strictly available only by prescription. In the United States, its use is limited to a highly restricted Investigational Limited Access Program (LAP) for specific, severe, refractory conditions.

Q: Does Cisap interact with supplements like St. John's Wort?

Official drug interaction warnings focus on the body's CYP3A4 metabolic pathway. Supplements like St. John's Wort are known to influence this pathway, which could potentially affect the stability of Cisapride in the body, though explicit warnings regarding this specific supplement may not be universally documented in official labeling.

Q: Does Cisap treat the cause or just the symptoms?

Cisapride is described as addressing the mechanical cause of motility disorders. It works by stimulating a specific receptor to increase the release of acetylcholine, which enhances the coordinated contractility of the smooth muscles in the gut.

Q: Does Cisap have a generic version available?

The active ingredient, cisapride, is the generic name. While the original brand-name product is discontinued or restricted, generic formulations of cisapride are generally available only through the authorized, restricted access programs.

Q: Why do some people need to have a heart test before starting Cisap?

A baseline 12-lead ECG (electrocardiogram) is required before starting this therapy to measure the heart's electrical activity (QTc interval). This test is a required procedure due to the drug’s potential to prolong the QTc interval, which is associated with a risk of serious cardiac arrhythmias.

Q: Is Cisap considered a first-line treatment for its primary indication?

Official eligibility criteria for Cisapride state that it is limited to use in patients who have severe, refractory gastrointestinal motility disorders that have failed other treatments. This requirement indicates that it is not considered a first-line therapy.

Q: Is Cisap a controlled substance?

No, official regulatory classification states that Cisapride is not classified as a controlled substance under the US Drug Enforcement Administration (DEA) scheduling system.

Cisapride must be stored in a manner that protects the product's integrity and prevents access by children, according to official regulatory documentation.

Storage Requirements

Disposal Instructions

Unused or expired Cisapride should not be flushed down the toilet. The official disposal method is to use a medicine take-back program. If a program is not available, follow the standard guidance of mixing the medication with an unappealing substance, sealing it in a bag, and disposing of it in the household trash.